MedTrace Logo

Weight Changes After Incretin-mimetics

NCT06795360 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-02-24

No results posted yet for this study

Summary

The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?

Conditions

  • Obesity and Obesity-related Medical Conditions

Interventions

OTHER

discontinuation of weight loss medication

Participants will be studied right before their injectable weight loss medication runs out, and 3 months later

Sponsors & Collaborators

  • University of Wisconsin, Milwaukee

    collaborator OTHER

  • Medical College of Wisconsin

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2031-11-30
Completion
2031-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06795360 on ClinicalTrials.gov